E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Total hip arthroplasty surgery |
|
E.1.1.1 | Medical condition in easily understood language |
Analgesia and pain relief therapy for total hip replacement surgery |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of our study is to evaluate the equivalence of supra-inguinal fascia iliaca block to pericapsular nerve group block and periarticular infiltration in 2-minute walk test (2MWT) performance at 24 hours after the intervention. |
|
E.2.2 | Secondary objectives of the trial |
We expect supra-inguinal fascia iliaca block (SFIB) block to be equivalent to pericapsular nerve group (PENG) block and periarticular infiltration in postoperative functional performance, without motor and quadriceps femoral impairment and with equivalent postoperative analgesia. If the hypothesis is correct, we could propose to integrate SFIB or PENG as first line in the postoperative analgesia strategy for this surgery. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients will be recruited during the preoperative anesthesia consultation. They will have to be of age (> 18 years old), classified in the categories American Society of Anesthesiologists (ASA) 1-2-3, admitted for a programmed total hip arthroplasty surgery with spinal anesthesia. |
|
E.4 | Principal exclusion criteria |
Excluded from the study are pregnant women, patients with peripheral neuropathy or other severe neurological pathology, chronic pain syndromes, chronic renal insufficiency or severe hepatic insufficiency, allergy to local anaesthetics, major haemostasis disorders or opioid addiction. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the assessment of performance on the 2-minute walking test |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 24 hours after surgery |
|
E.5.2 | Secondary end point(s) |
- Consumption of morphine equivalents: oral administration of oxycodone - The distance in meters covered in the 2-minute walk test - Distance in meters covered in the 6-minute walk test - Timed Up-and-Go (TUG) test - Numerical rating scale (NRS) of pain
- Postoperative complications such as: 1. Orthostatic intolerance 2. Falls 3. Postoperative nausea and vomiting 4. Morphine-related side effects: bladder globe, constipation, dizziness and drowsiness
- Tampa-scale for the measurement of kinesiophobia - Quality-of-Recovery 15-item score (QoR-15) to assess functional recovery
- Analysis of quadriceps strength before and after the intervention using the dynamometer for isometric contraction
- Analysis with the Inertial Measurment Units (IMUs) system with accelerometer technology and angular acceleration measurement |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Opioid consumption: first 24 hours postoperatively - 2-minute walk test: second postoperative day (D2). - Timed Up-and-Go (TUG) test and 6-minute walk test on the first (D1) and second (D2) day after surgery - NRS of pain at fixed times: 6h and 12h after surgery, at D1 at 8h, 13h and 18h.
First 48 hours for postoperative complications Tampa-scale for the measurement of kinesiophobia at D2 Quality-of-Recovery 15-item score (QoR-15) to assess functional recovery on day-2 and day-30 Analysis of quadriceps strength before and after the intervention using the dynamometer for isometric contraction at D1 and D2 Analysis with the Inertial Measurment Units (IMUs) system with accelerometer technology and angular acceleration measurement at D1 and D2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is reached at the last visit of the last subject at the end of hospitalization and/or day 30 after surgery |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |